The endocrine disrupting chemical tolylfluanid alters adipocyte metabolism via glucocorticoid receptor activation

Molecular Endocrinology

Volumn 27, Issue 3, 2013, Pages 394-406

  Neel, Brian A ^a   Brady, Matthew J ^a,b   Sargis, Robert M ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ENDOCRINE DISRUPTOR; GLUCOCORTICOID RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; LEUCINE ZIPPER PROTEIN; SERINE; TOLYLFLUANID; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL FRACTIONATION; CELL METABOLISM; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DRUG EXPOSURE; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HORMONE RECEPTOR INTERACTION; HORMONE RECEPTOR TRANSLOCATION; INSULIN SENSITIVITY; LIPOGENESIS; MALE; METABOLIC ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

3T3-L1 CELLS; ADIPOCYTES; ANILINE COMPOUNDS; ANIMALS; CELL NUCLEUS; COMPUTATIONAL BIOLOGY; CORTICOSTERONE; ENDOCRINE DISRUPTORS; GENE EXPRESSION REGULATION; HUMANS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; LIGANDS; LIPOGENESIS; MALE; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; PHOSPHORYLATION; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, GLUCOCORTICOID; RESPONSE ELEMENTS; SULFONAMIDES; TRANSCRIPTION FACTORS;

EID: 84874541214     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2012-1270     Document Type: Article

References (57)

1. Gregoire FM. Adipocyte differentiation: from fibroblast to endocrine cell. Exp Biol Med (Maywood). 2001;226(11):997-1002.
2. Gregoire FM, Smas CM, Sul HS. Understanding adipocyte differentiation. Physiol Rev. 1998;78(3):783-809.
3. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88(12):5593-5602.
4. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010; 303(3):235-241.
5. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: United States Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
6. Grun F, Watanabe H, Zamanian Z, et al. Endocrine-disrupting organotin compounds are potent inducers of adipogenesis in vertebrates. Mol Endocrinol. 2006;20(9):2141-2155.
7. Grun F, Blumberg B. Environmental obesogens: organotins and endocrine disruption via nuclear receptor signaling. Endocrinology. 2006;147(6 Suppl):S50-55.
8. Baillie-Hamilton PF. Chemical toxins: a hypothesis to explain the global obesity epidemic. J Altern Complement Med. 2002;8(2): 185-192.
9. Neel BA, Sargis RM. The paradox of progress: environmental disruption of metabolism and the diabetes epidemic. Diabetes. 2011; 60(7):1838-1848.
10. Sargis RM, Johnson DN, Choudhury RA, Brady MJ. Environmental endocrine disruptors promote adipogenesis in the 3T3-L1 cell line through glucocorticoid receptor activation. Obesity (Silver Spring). 2010;18(7):1283-1288.
11. Jugan ML, Levi Y, Blondeau JP. Endocrine disruptors and thyroid hormone physiology. Biochem Pharmacol. 2010;79(7):939-947.
12. Urbatzka R, van Cauwenberge A, Maggioni S, et al. Androgenic and antiandrogenic activities in water and sediment samples from the river Lambro, Italy, detected by yeast androgen screen and chemical analyses. Chemosphere. 2007;67(6):1080-1087.
13. Dickerson SM, Gore AC. Estrogenic environmental endocrine-disrupting chemical effects on reproductive neuroendocrine function and dysfunction across the life cycle. Rev Endocr Metab Disord. 2007;8(2):143-159.
14. Casals-Casas C, Desvergne B. Endocrine disruptors: from endocrine to metabolic disruption. Annu Rev Physiol. 2011;73:135-162.
15. Ruzzin J, Petersen R, Meugnier E, et al. Persistent organic pollutant exposure leads to insulin resistance syndrome. Environ Health Perspect. 2010;118(4):465-471.
16. Kirchner S, Kieu T, Chow C, Casey S, Blumberg B. Prenatal exposure to the environmental obesogen tributyltin predisposes multipotent stem cells to become adipocytes. Mol Endocrinol. 2010; 24(3):526-539.
17. Johnson KJ, McDowell EN, Viereck MP, Xia JQ. Species-specific dibutyl phthalate fetal testis endocrine disruption correlates with inhibition of SREBP2-dependent gene expression pathways. Toxicol Sci. 2011;120(2):460-474.
18. Bergman RN, Ader M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab. 2000;11(9):351-356.
19. Environmental Protection Agency (EPA). Pesticide Fact Sheet: Tolylfluanid. Washington, DC; United States Environmental Protection Agency; 2002.
20. Stepan R, Ticha J, Hajslova J, Kovalczuk T, Kocourek V. Baby food production chain: pesticide residues in fresh apples and products. Food Addit Contam. 2005;22(12):1231-1242.
21. Cesnik HB, Gregorcic A, Bolta SV, Kmecl V. Monitoring of pesticide residues in apples, lettuce and potato of the Slovene origin, 2001-04. Food Addit Contam. 2006;23(2):164-173.
22. Sadlo S, Szpyrka E, Jazwa A, Zawislak A. Pesticide residues in fruit and vegetables from southeastern Poland, 2004-05. Polish J of Environ Stud. 2007;16(2):313-219.
23. Stensvand A, Christiansen A. Investigation on fungicide residues in greenhouse-grown strawberries. J Agric Food Chem. 2000;48(3):917-920.
24. Konstantinou IK, Albanis TA. Worldwide occurrence and effects of antifouling paint booster biocides in the aquatic environment: a review. Environ Int. 2004;30(2):235-248.
25. Bellas J. Comparative toxicity of alternative antifouling biocides on embryos and larvae of marine invertebrates. Sci Total Environ. 2006;367(2-3):573-585.
26. Tielemans E, Louwerse E, de Cock J, Brouwer D, Zielhuis G, Heederik D. Exposure to fungicides in fruit growing: re-entry time as a predictor for dermal exposure. Am Ind Hyg Assoc J. 1999;60(6): 789-793.
27. Links I, Van Der Jagt KE, Christopher Y, et al. Occupational exposure during application and removal of antifouling paints. Ann Occup Hyg. 2007;51(2):207-218.
28. Johansson M, Johansson N, Lund BO. Xenobiotics and the glucocorticoid receptor: additive antagonistic effects on tyrosine aminotransferase activity in rat hepatoma cells. Basic Clin Pharmacol Toxicol. 2005;96(4):309-315.
29. Jurczak MJ, Danos AM, Rehrmann VR, Allison MB, Greenberg CC, Brady MJ. Transgenic overexpression of protein targeting to glycogen markedly increases adipocytic glycogen storage in mice. Am J Physiol Endocrinol Metab. 2007;292(3):E952-E963.
30. Lazar DF, Wiese RJ, Brady MJ, et al. Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin. J Biol Chem. 1995;270(35):20801-20807.
31. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455-461.
32. Seitz T, Thoma R, Schoch GA, et al. Enhancing the stability and solubility of the glucocorticoid receptor ligand-binding domain by high-throughput library screening. J Mol Biol. 2010;403(4):562-577.
33. Ayroldi E, Riccardi C. Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. FASEB J. 2009;23(11):3649-3658.
34. Sargis RM, Neel BA, Brock CO, et al. The novel endocrine disruptor tolylfluanid impairs insulin signaling in primary rodent and human adipocytes through a reduction in insulin receptor substrate-1 levels. Biochim Biophys Acta. 2012;1822(6):952-960.
35. Turnbow MA, Smith LK, Garner CW. The oxazolidinedione CP-92,768-2 partially protects insulin receptor substrate-1 from dexamethasone down-regulation in 3T3-L1 adipocytes. Endocrinology. 1995;136(4):1450-1458.
36. Chen W, Dang T, Blind RD, et al. Glucocorticoid receptor phosphorylation differentially affects target gene expression. Mol Endocrinol. 2008;22(8):1754-1766.
37. Yu CY, Mayba O, Lee JV, Tran J, Harris C, Speed TP, Wang JC. Genome-wide analysis of glucocorticoid receptor binding regions in adipocytes reveal gene network involved in triglyceride homeostasis. PLoS One. 2010;5(12):e15188.
38. Messeguer X, Escudero R, Farre D, Nunez O, Martinez J, Alba MM. PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics. 2002;18(2):333-334.
39. Folli F, Saad MJ, Kahn CR. Insulin receptor/IRS-1/PI 3-kinase signaling system in corticosteroid-induced insulin resistance. Acta Diabetol. 1996;33(3):185-192.
40. Saad MJ, Folli F, Araki E, Hashimoto N, Csermely P, Kahn CR. Regulation of insulin receptor, insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-F442A adipocytes. Effects of differentiation, insulin, and dexamethasone. Mol Endocrinol. 1994;8(5):545-557.
41. Saad MJ, Folli F, Kahn JA, Kahn CR. Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats. J Clin Invest. 1993;92(4):2065-2072.
42. Gathercole LL, Bujalska IJ, Stewart PM, Tomlinson JW. Glucocorticoid modulation of insulin signaling in human subcutaneous adipose tissue. J Clin Endocrinol Metab. 2007;92(11):4332-4339.
43. Kersten S. Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep. 2001;2(4):282-286.
44. Tong L. Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and attractive target for drug discovery. Cell Mol Life Sci. 2005; 62(16):1784-1803.
45. Wang Y, Jones Voy B, Urs S, et al. The human fatty acid synthase gene and de novo lipogenesis are coordinately regulated in human adipose tissue. J Nutr. 2004;134(5):1032-1038.
46. Zhao LF, Iwasaki Y, Zhe W, et al. Hormonal regulation of acetyl-CoA carboxylase isoenzyme gene transcription. Endocr J. 2010; 57(4):317-324.
47. Berdanier CD. Role of glucocorticoids in the regulation of lipogenesis. FASEB J. 1989;3(10):2179-2183.
48. Samra JS, Clark ML, Humphreys SM, MacDonald IA, Bannister PA, Frayn KN. Effects of physiological hypercortisolemia on the regulation of lipolysis in subcutaneous adipose tissue. J Clin Endocrinol Metab. 1998;83(2):626-631.
49. Cinar O, Seval Y, Uz YH, et al. Differential regulation of Akt phosphorylation in endometriosis. Reprod Biomed Online. 2009; 19(6):864-871.
50. Kitagawa K, Takasawa K, Kuwabara K, et al. Differential Akt phosphorylation at Ser473 and Thr308 in cultured neurons after exposure to glutamate in rats. Neurosci Lett. 2002;333(3):187-190.
51. Ouyang YB, Zhang XH, He QP, Wang GX, Siesjo BK, Hu BR. Differential phosphorylation at Ser473 and Thr308 of Akt-1 in rat brain following hypoglycemic coma. Brain Res. 2000;876(1-2): 191-195.
52. Vandenberg LN, Maffini MV, Sonnenschein C, Rubin BS, Soto AM. Bisphenol-A and the great divide: a review of controversies in the field of endocrine disruption. Endocr Rev. 2009;30(1):75-95.
53. Yachi K, Inoue K, Tanaka H, Yoshikawa H, Tohyama M. Localization of glucocorticoid-induced leucine zipper (GILZ) expressing neurons in the central nervous system and its relationship to the stress response. Brain Res. 2007;1159:141-147.
54. Williams JB, Pang D, Delgado B, et al. A model of gene-environment interaction reveals altered mammary gland gene expression and increased tumor growth following social isolation. Cancer Prev Res (Phila). 2009;2(10):850-861.
55. Cao H, Gerhold K, Mayers JR, Wiest MM, Watkins SM, Hotamisligil GS. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell. 2008;134(6):933-944.
56. Zhang W, Sargis RM, Volden PA, Carmean CM, Sun XJ, Brady MJ. PCB 126 and other dioxin-like PCBs specifically suppress hepatic PEPCK expression via the aryl hydrocarbon receptor. PLoS One. 2012;7(5):e37103.
57. Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods. 2001;25(4): 386-401.